CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 1.8×, higher than 95% of its Biotechnology peers (median 0.07×)
- FinancialsAltman Z-Score -1.05: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
346.01MUSDvs all stocks (USD)
Revenue (TTM)
65.26MUSDvs all stocks (USD)
Profit Margin
-96.89%vs Biotechnology peers
Beta
0.9380xvs all stocks
52-Week Change
-21.64%vs all stocks
Market Capitalization
346.01MUSDvs all stocks (USD)
Enterprise Value
338.54MUSDvs all stocks (USD)
Forward P/E
-5.00xvs Biotechnology peers
Price to Sales (TTM)
5.30xvs Biotechnology peers
Price to Book (MRQ)
3.42xvs Biotechnology peers
Enterprise to Revenue
5.19xvs Biotechnology peers
Enterprise to EBITDA
-6.29xvs Biotechnology peers
Profit Margin
-96.89%vs Biotechnology peers
Operating Margin
-120.04%vs Biotechnology peers
Return on Assets (TTM)
-12.28%vs Biotechnology peers
Return on Equity (TTM)
-70.12%vs Biotechnology peers
Revenue (TTM)
65.26MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.41USDUpdated Sep 27, 2026Quarterly Revenue Growth
-21.60%vs Biotechnology peers
Gross Profit (TTM)
65.26MUSDvs all stocks (USD)
EBITDA (TTM)
-53.82MUSDvs all stocks (USD)
Net Income (TTM)
-63.23MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-35.32MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-22.66MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
65.32MUSDFY2025 · Sep 30, 2025Operating Income
-85.35MUSDvs all stocks (USD)
Pre-tax Income
-83.55MUSDFY2025 · Sep 30, 2025Income Tax Expense
-1.66MUSDFY2025 · Sep 30, 2025Net Income
-81.89MUSDFY2025 · Sep 30, 2025EBIT
-75.87MUSDFY2025 · Sep 30, 2025EBITDA (Income Statement)
-71.32MUSDFY2025 · Sep 30, 2025Research & Development
106.74MUSDFY2025 · Sep 30, 2025Selling, General & Administrative
43.93MUSDFY2025 · Sep 30, 2025Non-operating Interest Income
9.44MUSDFY2025 · Sep 30, 2025Non-operating Interest Expense
7.68MUSDFY2025 · Sep 30, 2025EPS (Basic)
-3.84USDFY2025 · Sep 30, 2025EPS (Diluted)
-3.84USDFY2025 · Sep 30, 2025Basic Shares Outstanding
21.34MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
21.34MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-81.89MUSDFY2025 · Sep 30, 2025Operating Cash Flow
-23.66MUSDFY2025 · Sep 30, 2025Free Cash Flow
-36.56MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
35.66MUSDFY2025 · Sep 30, 2025Income Tax Paid
109.00KUSDFY2025 · Sep 30, 2025Interest Paid
8.79MUSDFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-81.89MUSDFY2025 · Sep 30, 2025Depreciation & Amortization
4.59MUSDFY2025 · Sep 30, 2025Stock-based Compensation
18.57MUSDFY2025 · Sep 30, 2025Other Non-cash Items
-952.00KUSDFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
31.76MUSDFY2025 · Sep 30, 2025Change in Accounts Payable (CF)
-1.31MUSDFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
5.58MUSDFY2025 · Sep 30, 2025Capital Expenditures
-12.90MUSDFY2025 · Sep 30, 2025Purchase of Investments
-209.63MUSDFY2025 · Sep 30, 2025Sale of Investments
262.87MUSDFY2025 · Sep 30, 2025Net Investing Cash Flow
40.35MUSDFY2025 · Sep 30, 2025Other Financing Charges
-26.76MUSDFY2025 · Sep 30, 2025Net Financing Cash Flow
-26.76MUSDFY2025 · Sep 30, 2025Shares Outstanding
29.12MSharesUpdated Sep 27, 2026Float Shares
22.52MSharesUpdated Sep 27, 2026Shares Short
2.60MSharesUpdated Sep 27, 2026Short Ratio
10.24daysvs all stocks
Short % of Shares Outstanding
10.68%vs all stocks
% Held by Insiders
4.67%vs all stocks
% Held by Institutions
94.37%vs all stocks
Total Cash (MRQ)
189.51MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.51USDUpdated Sep 27, 2026Total Debt (MRQ)
182.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.80xvs Biotechnology peers
Current Ratio (MRQ)
3.76xvs Biotechnology peers
Book Value per Share (MRQ)
3.47USDUpdated Sep 27, 2026Total Assets
280.73MUSDvs all stocks (USD)
Total Current Assets
204.34MUSDFY2025 · Sep 30, 2025Total Liabilities
216.01MUSDFY2025 · Sep 30, 2025Total Non-current Assets
76.40MUSDFY2025 · Sep 30, 2025Total Non-current Liabilities
167.46MUSDFY2025 · Sep 30, 2025Total Current Liabilities
48.55MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents
32.30MUSDFY2025 · Sep 30, 2025Other Short-term Investments
156.57MUSDFY2025 · Sep 30, 2025Accounts Receivable
6.88MUSDFY2025 · Sep 30, 2025Accounts Payable
1.95MUSDFY2025 · Sep 30, 2025Short-term Debt
3.15MUSDFY2025 · Sep 30, 2025Other Current Liabilities
30.71MUSDFY2025 · Sep 30, 2025Long-term Debt
54.76MUSDFY2025 · Sep 30, 2025Other Non-current Liabilities
111.39MUSDFY2025 · Sep 30, 2025Common Stock (Book)
214.00KUSDFY2025 · Sep 30, 2025Retained Earnings
-404.93MUSDFY2025 · Sep 30, 2025Total Shareholders' Equity
64.72MUSDvs all stocks (USD)
52-Week Low
7.05USDUpdated Sep 27, 202652-Week High
17.15USDUpdated Sep 27, 202652-Week Change
-21.64%vs all stocks
Beta
0.9380xvs all stocks
50-Day MA
13.14USDUpdated Sep 27, 2026200-Day MA
13.54USDUpdated Sep 27, 2026Avg 10-Day Volume
255.01KSharesUpdated Sep 27, 2026Avg 30-Day Volume
249.68KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-2.42USDUpdated Sep 27, 2026Other Income / Expense
39.00KUSDFY2025 · Sep 30, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.8×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.80Industry median: 0.07Industry P95: 0.86Peers compared: 258
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 189,506,000Total Debt (USD): 182,040,000Debt-to-Equity: 1.80
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.76Altman Z-Score: -1.05
Financial Health
Altman Z-Score -1.05: distress zoneCritical
Altman Z-Score: -1.05
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule